About this document

Dapagliflozin in Type 1 Diabetes: DEPICT-1 Results by GVR is a document available to read on EtoBox.

This document summarizes the results of a 24-week clinical trial that assessed the efficacy and safety of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, as an add-on treatment to insulin in patients with inadequately controlled type 1 diabetes. The trial found that both 5 mg and 10 mg doses of dapagliflozin significantly reduced HbA1c levels compared to placebo. Adverse events were generally similar between dapagliflozin and placebo groups, though definite diabetic ketoacidosis occurred in 1-2%

Author

GVR

Language

EN